Medicago/GSK’s COVID-19 Vaccine 71% Effective: PII/III

December 8, 2021
A plant-derived COVID-19 vaccine being developed by Medicago, a Canadian subsidiary of Mitsubishi Tanabe Pharma, using GlaxoSmithKline’s pandemic adjuvant was 71% effective against multiple variants in a placebo-controlled PII/III study, the companies said on December 7. The companies confirmed the...read more